+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Hyperoxaluria Drug"

Hyperoxaluria - Pipeline Insight, 2024 - Product Thumbnail Image

Hyperoxaluria - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 50 Pages
  • Global
From
Primary Hyperoxaluria - Pipeline Insight, 2024 - Product Thumbnail Image

Primary Hyperoxaluria - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
OXLUMO Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

OXLUMO Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • July 2023
  • 30 Pages
  • Global
From
Primary Hyperoxaluria - Epidemiology Forecast - 2032 - Product Thumbnail Image

Primary Hyperoxaluria - Epidemiology Forecast - 2032

  • Drug Pipelines
  • February 2022
  • 76 Pages
  • Global
From
Primary Hyperoxaluria - Pipeline Review, H2 2019 - Product Thumbnail Image

Primary Hyperoxaluria - Pipeline Review, H2 2019

  • Drug Pipelines
  • November 2019
  • 63 Pages
  • Global
From
From
  • 7 Results (Page 1 of 1)
Loading Indicator

Hyperoxaluria is a disorder of the liver and kidneys caused by an excess of oxalate in the body. It is typically treated with drugs that reduce the amount of oxalate produced by the body, or that increase the amount of oxalate excreted in the urine. These drugs are used to reduce the risk of kidney stones, kidney damage, and other complications associated with hyperoxaluria. Common drugs used to treat hyperoxaluria include allopurinol, pyridoxine, and calcium citrate. The hyperoxaluria drug market is a niche market, with a limited number of drugs available to treat the disorder. The market is expected to grow in the coming years, as more drugs are developed to treat hyperoxaluria and its associated complications. Some companies in the hyperoxaluria drug market include Pfizer, Merck, and Sanofi. Show Less Read more